<DOC>
	<DOCNO>NCT00687362</DOCNO>
	<brief_summary>Middle Eastern subject moderate-to-severe chronic plaque psoriasis administer infusion infliximab ( Remicade ) 5 mg/kg body weight Weeks 0 , 2 , 6 , 14 , 22 . The safety efficacy infliximab monotherapy evaluate .</brief_summary>
	<brief_title>A Study Evaluate Remicade ( Infliximab ) Moderate-to-Severe Chronic Plaque Psoriasis Middle Eastern Population ( Study P04528 )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>18 year old , either gender , race . Psoriasis affect &gt; =5 % body surface , PASI score &gt; =10 ( maximum score 72 ) . History plaque psoriasis &gt; 6 month . Informed write consent . Refractory antipsoriasis agent ( topical corticosteroid , phototherapy UVa [ PUVA ] , systemic therapy ) . Negative chest xray purify protein derivative ( PPD ) within 1 month . Understand able adhere dose visit schedule . Screening laboratory test must meet protocolspecified criterion . Women men childbearing potential must use adequate birth control measure continue precaution 6 month last infusion infliximab . Pregnant , nursing , plan pregnancy within 6 month last scheduled treatment . Used topical corticosteroid previous 14 day systemic therapy ( phototherapy UVb [ UVB ] , PUVA , cyclosporine , methotrexate ) previous 28 day , receive treatment antitumor necrosis factor ( TNF ) alpha monoclonal antibody , human murine immunoglobulin , TNFalpha receptor fusion protein , bioengineered fusion protein . Received previous immunobiologics . Have HIV , hepatitis B C. Recently transplant ( exception corneal transplant &gt; 3 month prior first infusion ) know malignancy history malignancy within previous 5 year ( exception basal squamous cell carcinoma skin treat evidence recurrence ) . Concurrent medication permit . congestive heart failure ( CHF ) Use cyclosporine tacrolimus within 4 week prior Screening . Use intramuscular ( IM ) , intravenous ( IV ) , oral corticosteroid within 4 week prior Screening . Treatment investigational drug within 3 month prior Screening . Allergy murine protein . Serious infection ( hepatitis , pneumonia , pyelonephritis ) previous 3 month . History active tuberculosis ( TB ) require treatment within previous 3 year , history opportunistic infection ( herpes zoster ) within 2 month Screening . Current sign symptom severe , progressive uncontrolled renal , hepatic , hematologic , endocrine , pulmonary , cardiac , neurological cerebral disease . Current sign symptom severe uncontrolled disease investigator 's opinion would put subject unacceptable risk . History current alcohol drug abuse . Not observe designate washout period prohibit medication protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>